A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.

导出 OA

翻译打印收藏纠错

作者： Josep,Tabernero ^[1] ; Eric,Van Cutsem ^[2] ; Elena,Garralda ^[3] ; David,Tai ^[4] ; Filippo,De Braud ^[5] ; Ravit,Geva ^[6] ; Mark T J,van Bussel ^[7] ; Katia,Fiorella Dotti ^[5] ; Elena,Elez ^[8] ; María J,de Miguel ^[3] ; Kevin,Litwiler ^[9] ; Danielle,Murphy ^[10] ; Michelle,Edwards ^[11] ; Van Karlyle,Morris ^[12]

作者单位： Vall d'Hebron Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain. ^[1] University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. ^[2] START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain. ^[3] Division of Medical Oncology, National Cancer Centre Singapore, Singapore. ^[4] Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[5] Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. ^[6] Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[7] Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain. ^[8] Pfizer, Boulder, CO, USA. ^[9] Pfizer, La Jolla, CA, USA. ^[10] Pfizer, New York, NY, USA. ^[11] Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[12]

关键词 WNT974 cetuximab colorectal cancer encorafenib metastatic

主题词人类(Humans);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));高钙血症(Hypercalcemia);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);结直肠肿瘤(Colorectal Neoplasms);突变(Mutation)

DOI 10.1093/oncolo/oyad007

PMID 36811382

发布时间 2024-09-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交